Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1976 1
1977 1
1979 3
1980 1
1981 4
1982 2
1983 1
1984 1
1985 6
1986 1
1988 1
1989 1
1990 1
1991 1
1992 4
1993 1
1994 1
1995 1
1996 2
1997 1
1998 4
1999 1
2000 3
2001 2
2002 2
2003 4
2004 7
2005 9
2006 3
2007 4
2008 2
2009 8
2010 10
2011 7
2012 8
2013 5
2014 8
2015 13
2016 5
2017 10
2018 8
2019 9
2020 3
2021 6
2022 13
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Results by year

Filters applied: . Clear all
Page 1
Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia.
Farber A, Menard MT, Conte MS, Kaufman JA, Powell RJ, Choudhry NK, Hamza TH, Assmann SF, Creager MA, Cziraky MJ, Dake MD, Jaff MR, Reid D, Siami FS, Sopko G, White CJ, van Over M, Strong MB, Villarreal MF, McKean M, Azene E, Azarbal A, Barleben A, Chew DK, Clavijo LC, Douville Y, Findeiss L, Garg N, Gasper W, Giles KA, Goodney PP, Hawkins BM, Herman CR, Kalish JA, Koopmann MC, Laskowski IA, Mena-Hurtado C, Motaganahalli R, Rowe VL, Schanzer A, Schneider PA, Siracuse JJ, Venermo M, Rosenfield K; BEST-CLI Investigators. Farber A, et al. Among authors: mckean m. N Engl J Med. 2022 Dec 22;387(25):2305-2316. doi: 10.1056/NEJMoa2207899. Epub 2022 Nov 7. N Engl J Med. 2022. PMID: 36342173 Clinical Trial.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Weber JS, et al. Among authors: mckean m. Lancet. 2024 Feb 17;403(10427):632-644. doi: 10.1016/S0140-6736(23)02268-7. Epub 2024 Jan 18. Lancet. 2024. PMID: 38246194 Clinical Trial.
Childhood cough.
Brodlie M, Graham C, McKean MC. Brodlie M, et al. Among authors: mckean mc. BMJ. 2012 Mar 6;344:e1177. doi: 10.1136/bmj.e1177. BMJ. 2012. PMID: 22395925 Review. No abstract available.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
de Braud F, Dooms C, Heist RS, Lebbe C, Wermke M, Gazzah A, Schadendorf D, Rutkowski P, Wolf J, Ascierto PA, Gil-Bazo I, Kato S, Wolodarski M, McKean M, Muñoz Couselo E, Sebastian M, Santoro A, Cooke V, Manganelli L, Wan K, Gaur A, Kim J, Caponigro G, Couillebault XM, Evans H, Campbell CD, Basu S, Moschetta M, Daud A. de Braud F, et al. Among authors: mckean m. J Clin Oncol. 2023 May 10;41(14):2651-2660. doi: 10.1200/JCO.22.02018. Epub 2023 Mar 22. J Clin Oncol. 2023. PMID: 36947734 Clinical Trial.
Should we use montelukast in wheezy children?
Haq I, Harris C, Taylor J, McKean MC, Brodlie M. Haq I, et al. Among authors: mckean mc. Arch Dis Child. 2017 Nov;102(11):997-998. doi: 10.1136/archdischild-2017-312655. Epub 2017 Aug 5. Arch Dis Child. 2017. PMID: 28780506 No abstract available.
Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD, McKean M. Lietman CD, et al. Among authors: mckean m. Cancer Gene Ther. 2022 Dec;29(12):1809-1813. doi: 10.1038/s41417-022-00437-6. Epub 2022 Feb 18. Cancer Gene Ther. 2022. PMID: 35181742 Review.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. Postel-Vinay S, et al. Among authors: mckean m. J Immunother Cancer. 2023 Mar;11(3):e005301. doi: 10.1136/jitc-2022-005301. J Immunother Cancer. 2023. PMID: 36927527 Free PMC article. Clinical Trial.
171 results